Latest News - Almirall

Thursday, January 17, 2019

Almirall's Seysara Now Available

SeysaraTM (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne, is now commercially available from Almirall. Seysara™ was approved in…

Read the full story

Wednesday, December 12, 2018

Almirall and X-Chem Team Up to Develop Oral Compounds for Dermatological Diseases

Almirall, S.A. signed a collaborative research and license agreement with the X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases, a strategic area f…

Read the full story

Tuesday, October 23, 2018

Almirall, LLC is the New Name of Aqua

Almirall, LLC is the new name of Aqua Pharmaceuticals. Almirall, LLC is part of the larger Almirall, S.A. family, an internationally-recognized global dermatology pharmaceutical company, wit…

Read the full story

Thursday, October 18, 2018

Almirall’s Seysara Set to Shake Up US Acne Market

The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients age…

Read the full story

Wednesday, October 10, 2018

AlmirallShare Issues Call for Proposals

Almirall is seeking to find novel targets and concepts in the treatment of dermatological diseases. The company’s AlmirallShare open innovation platform is calling for proposals from Octobe…

Read the full story

Tuesday, October 02, 2018

Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Years

Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients…

Read the full story

Friday, September 21, 2018

Almirall Finalizes Acquisition of Allergan US Medical Dermatology Portfolio

Almirall, S.A. finalized its acquisition of products from Allergan's Medical Dermatology unit in the US: Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), and Cordran Tape (flurandren…

Read the full story

Monday, September 17, 2018

Almirall and Evotec Form Dermatology Research Collaboration

Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debi…

Read the full story

Wednesday, September 05, 2018

New from Thermi: Meet the Arvati Platform

Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequency platform that powers a range of Thermi proc…

Read the full story